Evidence map›Paper›PMID 30107760›Full record

ArticleDrug delivery2018

Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease.

Shengnuo Fan, Yuqiu Zheng, Xuan Liu, Wenli Fang, Xiaoyu Chen, Wang Liao, Xiuna Jing, Ming Lei, Enxiang Tao, Qiulan Ma and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 246 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Alzheimer's disease: unraveling role of xanthone derivatives and nanocarriers.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  18. Review
  19. Review
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Shengnuo Fana Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Yuqiu Zhenga Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Xuan Liub Key Laboratory of Biomaterials of Guangdong Higher Education Institutes Department of Biomedical Engineering , Jinan University , Guangzhou , China.
Wenli Fanga Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Xiaoyu Chena Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Wang Liaoa Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Xiuna Jinga Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Ming Leia Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Enxiang Taoa Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Qiulan Mad Department of Neurology , University of California , Los Angeles , CA , USA.
Xingmei Zhange Applied Immunology and Immunotherapy, Department of Clinical Neuroscience , Karolinska Institute, Center for Molecular Medicine, Karolinska University Hospital at Solna , Stockholm , Sweden.
Rui Guob Key Laboratory of Biomaterials of Guangdong Higher Education Institutes Department of Biomedical Engineering , Jinan University , Guangzhou , China.
Jun Liua Department of Neurology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China.
Sun Yat-sen University · CNJinan University · CNSun Yat-sen Memorial Hospital · CNKarolinska Institutet · SEUniversity of California, Los Angeles · USZhongshan People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease is a neurodegenerative disorder mainly characterized by β-amyloid deposit and tau hyperphosphorylation with no curative treatments. Curcumin (Cur) has been proved to have potential use in Alzheimer's disease with its anti-amyloid, anti-inflammatory, and anti-oxidant properties, etc. However, its hydrophobicity and low bioavailability hinder its application. In this paper, we designed a novel brain-target nanoparticle, poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG) conjugated with B6 peptide and was loaded with Cur (PLGA-PEG-B6/Cur) and administered it into HT22 cells and APP/PS1 Al transgenic mice. The in vitro assays including dynamic light scattering (DLS), flow cytometry (FCM), red blood cell (RBC) lysis, and thromboelastography (TEG) analysis indicated that this nanoparticle could narrow the diameter of Cur, increase its cellular uptake and possess good blood compatibility. The results from Morris water maze proved that PLGA-PEG-B6/Cur could tremendously improve the spatial learning and memory capability of APP/PS1 mice, compared with native Cur. The ex vivo assays including Bielschowsky silver staining, immunostaining, and western blotting demonstrated that PLGA-PEG-B6/Cur could reduce hippocampal β-amyloid formation and deposit and tau hyperphosphorylation. Thus, we suggested that PLGA-PEG-B6/Cur nanoparticles would be of potential and promising use for the treatment of Alzheimer's disease.

Indexed as

Alzheimer DiseaseAnimalsBiocompatible MaterialsBiological AvailabilityCell LineCurcuminDrug CarriersDrug CompoundingHumansHydrophobic and Hydrophilic InteractionsMiceMolecular Targeted TherapyNanoparticlesOligopeptidesPolyestersPolyethylene GlycolsB6 peptideBiocompatible MaterialsCurcuminDrug CarriersOligopeptidesPolyesterspolyethylene glycol-poly(lactide-co-glycolide)Polyethylene GlycolsAlzheimer’s diseaseB6 peptideblood compatibilityCurcuminnanoparticles

Identifiers

PMID30107760
PMCPMC6116673
OpenAlexW2886328984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.